Clincosm LogoSign in Get a demo

Ketohexokinase Isoforms in Endometrial Cancer.

Sponsor
Far Eastern Memorial Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03931265
Collaborator
Gynecologic Oncology Group (Other)
220
Enrollment
1
Location
68.7
Anticipated Duration (Months)
3.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: ketohexokinase

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
220 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Prognostic Evaluations of Ketohexokinase Isoforms in Endometrial Cancer
Actual Study Start Date :
Apr 11, 2019
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Outcome Measures

Primary Outcome Measures

  1. The role of ketohexokinase isoforms in the overall survival of endometrial cancer. [5 years]

    Cox proportional hazard regression to evaluate the role of ketohexokinase isoforms in the overall survival of endometrial cancer.

Secondary Outcome Measures

  1. Correlation of ketohexokinase isoforms with the other prognostic risk factors [5 years]

    Correlation of ketohexokinase isoforms with deep myometrial invasion, tumor grade, lymph node metastasis, FIGO stage, tumor size, progression-free survival, etc.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • 20 years

  • Women with endometrial cancer who are about to be admitted to hospital for gynecological staging.

  • Women who have undergone gynecological staging surgery for endometrial cancer in the past.

Exclusion Criteria:
  • Women with endometrial cancer who receive preoperative chemotherapy or radiation therapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital Banqiao New Taipei Taiwan 22050

Sponsors and Collaborators

  • Far Eastern Memorial Hospital
  • Gynecologic Oncology Group

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier:
NCT03931265
Other Study ID Numbers:
  • 108009-F
First Posted:
Apr 30, 2019
Last Update Posted:
Jun 15, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Endometrial Neoplasms

Study Results

No Results Posted as of Jun 15, 2022